Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 36

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
 operating decision maker (“CODM”), its Founder and Chief Executive Officer, assesses performance based on condensed consolidated net loss as reported on the condensed consolidated statement of operations and comprehensive loss, supplemented by certain additional significant expense details reflected in the table below. There have been no changes in the determination of segmentation or the measurements used to determine reported segment loss or segment total assets discussed in the Company's FY 2024 Form 10-K.

16

Table of Contents

Segment revenue and significant segment expenses which are regularly reported to the CODM are included within the table below and are reconciled to condensed consolidated net loss:Three months ended September 30,Nine months ended September 30,2025202420252024Revenue$143 $— $1,535 $1,039 Less:Research and development expensesPaltusotine(18,823)(13,689)(50,552)(39,710)Atumelnant(15,072)(6,430)(33,982)(15,595)Early research and development programs(9,264)(6,598)(25,928)(18,497)Research and development personnel expenses(26,062)(17,617)(76,827)(50,489)Research and development stock-based compensation(13,003)(10,556)(37,921)(29,612)Other research and development (1)(8,240)(7,015)(21,795)(19,687)Total research and development expenses(90,464)(61,905)(247,005)(173,590)Selling, general and administrativeExternal selling, general and administrative expenses(25,480)(9,272)(63,753)(26,807)Selling, general and administrative personnel expenses(17,086)(9,029)(42,497)(23,822)Selling, general and administrative stock-based compensation(9,699)(7,591)(31,383)(20,929)Total selling, general and administrative expenses(52,265)(25,892)(137,633)(71,558)Total other income, net12,495 10,969 40,601 26,766 Loss on equity method investment— — — (470)Segment and consolidated net loss$(130,091)$(76,828)$(342,502)$(217,813)(1)Other research and development is comprised of non-personnel related research and development indirect costs incurred for the benefit of multiple research and development programs